Orphazyme A/S
Company announcement                                                                                                                  
No. 10/2019                                                                                                                                        
Company Registration No. 32266355                                                                                                                                                                                       

 

Copenhagen, March 27, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today held its Annual General Meeting, at which the Annual General Meeting:

• took note of the Board of Directors’ report on the Company’s activities in the past financial year
• adopted the Company’s Annual Report 2018
• adopted that the loss related to the financial year 2018 is carried forward
• granted discharge of liability to the Board of Directors and the Executive Management in relation to the Annual Report 2018
• approved the remuneration of the Board of Directors for the current financial year
• re-elected Georges Gemayel, Bo Jesper Hansen, Martin Bonde, Rémi Droller, Sten Verland, Martijn Kleijwegt, Anders Hedegaard, and Catherine Moukheibir as members of the Board of Directors
• re-elected ERNST & YOUNG Godkendt Revisionspartnerselskab as the Company’s auditor in accordance with the recommendation from the Audit Committee, and
• approved the revised Remuneration Policy.

After the Company’s Annual General Meeting was held, the Board of Directors constituted itself by appointing Georges Gemayel as Chairman and Bo Jesper Hansen as Deputy Chairman of the Board of Directors.

 

For additional information, please contact

Orphazyme A/S
Anders Vadsholt, CFO                         +45 28 98 90 55

 

About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.

Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

 

Attachment

Resolutions passed at the annual general meeting

by Michael Hove